0.8446
Precedente Chiudi:
$0.8907
Aprire:
$0.8971
Volume 24 ore:
322.09K
Relative Volume:
1.28
Capitalizzazione di mercato:
$37.20M
Reddito:
$19.94M
Utile/perdita netta:
$-37.37M
Rapporto P/E:
-0.8121
EPS:
-1.04
Flusso di cassa netto:
$-33.38M
1 W Prestazione:
+1.78%
1M Prestazione:
-18.00%
6M Prestazione:
-71.47%
1 anno Prestazione:
-87.49%
Werewolf Therapeutics Inc Stock (HOWL) Company Profile
Nome
Werewolf Therapeutics Inc
Settore
Industria
Telefono
617-952-0555
Indirizzo
200 TALCOTT AVENUE, WATERTOWN
Confronta HOWL con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
HOWL
Werewolf Therapeutics Inc
|
0.8446 | 37.20M | 19.94M | -37.37M | -33.38M | -1.04 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
496.49 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
610.86 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
620.97 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
254.85 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
249.46 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Werewolf Therapeutics Inc Stock (HOWL) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2024-04-03 | Iniziato | JMP Securities | Mkt Outperform |
2023-08-24 | Iniziato | Wedbush | Outperform |
2023-06-06 | Ripresa | Jefferies | Buy |
2021-09-10 | Iniziato | BofA Securities | Buy |
2021-05-25 | Iniziato | Evercore ISI | Outperform |
2021-05-25 | Iniziato | H.C. Wainwright | Buy |
2021-05-25 | Iniziato | Jefferies | Buy |
2021-05-25 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Werewolf Therapeutics Inc Borsa (HOWL) Ultime notizie
Earnings Preview: Werewolf Therapeutics, Inc. (HOWL) Q1 Earnings Expected to Decline - Yahoo Finance
Werewolf Therapeutics (HOWL) Expected to Announce Quarterly Earnings on Friday - Defense World
Werewolf Therapeutics stock maintains $4 target, Market Outperform By Investing.com - Investing.com India
Werewolf Therapeutics stock maintains $4 target, Market Outperform - Investing.com
Werewolf Therapeutics Appoints Steven Bloom as Chief Business Officer - GlobeNewswire
Cancer Drug Developer Werewolf Therapeutics Strengthens Leadership Team Amid Promising Clinical Results - Stock Titan
Werewolf Therapeutics names Steven Bloom as CBO - The Pharma Letter
Werewolf Therapeutics stock hits 52-week low at $0.85 - Investing.com Australia
Werewolf Therapeutics stock hits 52-week low at $0.85 By Investing.com - Investing.com South Africa
Werewolf Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference - GlobeNewswire
Werewolf Therapeutics Reveals Latest Cancer Treatment Progress at Major Healthcare Conference - Stock Titan
Bank of New York Mellon Corp Grows Stake in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) - Defense World
Werewolf Therapeutics stock hits 52-week low at $1.02 By Investing.com - Investing.com Australia
Werewolf Therapeutics stock hits 52-week low at $1.02 - Investing.com India
Werewolf Therapeutics Reports 2024 Financial Results and Progress - TipRanks
HC Wainwright Issues Pessimistic Outlook for HOWL Earnings - Defense World
Wedbush Research Analysts Cut Earnings Estimates for HOWL - Defense World
HC Wainwright Reaffirms Buy Rating for Werewolf Therapeutics (NASDAQ:HOWL) - Defense World
Wedbush Reaffirms Outperform Rating for Werewolf Therapeutics (NASDAQ:HOWL) - Defense World
Werewolf Therapeutics Full Year 2024 Earnings: EPS Misses Expectations - Yahoo Finance
Werewolf Therapeutics Faces Geopolitical Risks Amid Changing Trade Policies with China - TipRanks
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - GlobeNewswire
Werewolf Therapeutics Inc. (HOWL) reports earnings - Quartz
Werewolf Therapeutics reports Q4 EPS (46c), consensus (31c) - TipRanks
Werewolf Therapeutics, Inc. SEC 10-K Report - TradingView
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides - Bakersfield.com
HOWLWerewolf Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Werewolf Therapeutics to Present at the 2025 Leerink Partners Global Biopharma Conference - GlobeNewswire
What Will Werewolf Therapeutics Reveal at the Leerink Biopharma Conference Next Month? - StockTitan
Werewolf Therapeutics, Inc. Announces Board Changes and Committee Appointment - Marketscreener.com
Werewolf Therapeutics (HOWL) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Werewolf Therapeutics stock hits 52-week low at $1.25 By Investing.com - Investing.com Canada
Werewolf Therapeutics stock hits 52-week low at $1.25 - Investing.com
Werewolf Therapeutics Announces Board Resignation and New Appointment - Defense World
Werewolf Therapeutics Appoints Anil Singhal, Ph.D., to its Board of Directors - GlobeNewswire
Werewolf Therapeutics appoints new board member By Investing.com - Investing.com South Africa
Werewolf Therapeutics appoints new board member - Investing.com India
Can This Oncology Pioneer Transform Werewolf's Cancer-Fighting Platform? - StockTitan
Oramed Pharmaceuticals And 2 Other US Penny Stocks To Watch - Simply Wall St
Arvinas, Inc. (ARVN) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Short Interest Update - MarketBeat
Harmony Biosciences (NASDAQ:HRMY) vs. Werewolf Therapeutics (NASDAQ:HOWL) Head to Head Review - Defense World
Barclays PLC Increases Stake in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) - Defense World
Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Short Interest Up 13.2% in December - MarketBeat
Werewolf Therapeutics Inc Azioni (HOWL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):